PVLA
PALVELLA THERAPEUTICS, INC.
$108.81
+2.28%
$1.6B
No data for this timeframe.
Vol
Market Cap$1.6B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (96%)
Inst. Holders50 funds
Inst. Value$720.2M
Inst. Activity13 buys / 3 sells
Insider Activity3B / 4S
Insider Net $-$216.5K
Reddit Sentiment50° Neutral
SEC Reports9
Press Releases7
Recent Activity
Jun 11, 2026
SEC
Three mega-passive institutional investors (Vanguard, State Street, Fidelity) significantly increased their PVLA holding
INST-CLUSTER — Impact 3/10
Jun 10, 2026
Insider
KIRITSY CHRISTOPHER P was granted 3,000 shares
Director
Jun 10, 2026
Insider
HERON ELAINE J was granted 3,000 shares
Director
Jun 10, 2026
Insider
JENKINS GEORGE M was granted 3,000 shares
Director
Jun 3, 2026
other
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
<p align="center"><em>Palvella remains on track to submit an NDA in the second half of 2026</em></p>
May 15, 2026
Press
Palvella presented positive Phase 2 TOIVA data at SID showing QTORIN rapamycin statistically significantly reduced bleed
Impact 7/10
May 15, 2026
SEC
Palvella Therapeutics announced new Phase 2 TOIVA trial data for QTORIN rapamycin in cutaneous venous malformations, pre
8-K — Impact 4/10
May 13, 2026
SEC
Palvella Therapeutics received approval from Nasdaq to transfer its common stock listing from the Nasdaq Capital Market
8-K — Impact 2/10
Price Targets
$229.60
+111.0% upside
Strong Buy
Current $108.81
Low $205.00
Median $225.00
High $270.00
15 analysts
$205.00
$270.00
Analyst Ratings
7Strong Buy
15Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 21, 2026 | Stephens & Co. | REITERATE | Overweight → Overweight |
| May 21, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| May 12, 2026 | Stephens & Co. | INITIATE | Overweight |
| Mar 31, 2026 | Chardan Capital | MAINTAIN | Buy → Buy |
| Mar 24, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-1.16 | $-1.42 — $-0.86 | -34% YoY | 12 |
| Next Q | $-1.47 | $-1.81 — $-1.05 | -42% YoY | 12 |
| Current FY | $-5.57 | $-6.91 — $-3.45 | -50% YoY | 13 |
| Next FY | $-6.82 | $-11.16 — $-1.54 | -23% YoY | 11 |
Latest Reports
NEUTRAL
INST-CLUSTER
3/10
Three mega-passive institutional investors (Vanguard, State Street, Fidelity) significantly increased their PVLA holding
Jun 11, 2026
BULLISH
Press
7/10
Palvella presented positive Phase 2 TOIVA data at SID showing QTORIN rapamycin statistically significantly reduced bleed
May 15, 2026
NEUTRAL
8-K
4/10
Palvella Therapeutics announced new Phase 2 TOIVA trial data for QTORIN rapamycin in cutaneous venous malformations, pre
May 15, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $85.6M | — |
| JENNISON ASSOCIATES LLC | $79.9M | ADD |
| VANGUARD CAPITAL MANAGEMENT LLC | $59.5M | — |
| STATE STREET CORP | $57.2M | DOUBLED |
| FEDERATED HERMES, INC. | $54.0M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 10, 2026 | KIRITSY CHRISTOPHER | A | $0.00 |
| Jun 10, 2026 | HERON ELAINE | A | $0.00 |
| Jun 10, 2026 | JENKINS GEORGE | A | $0.00 |
| May 20, 2026 | Goin Kathleen | M | $15.4K |
| May 20, 2026 | Goin Kathleen | SELL | $371.1K |
Reddit Sentiment
50°
Neutral
Bearish
Neutral
Bullish
50 institutional holders with $720.2M total value (5,824,349 shares) as of 2026-Q1. Top holders: BlackRock,, JENNISON, VANGUARD. Net buying activity: 13 institutions added/increased vs 3 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 686,853 | $85.6M | 11.9% | — |
| 2 | JENNISON ASSOCIATES LLC | 640,611 | $79.9M | 11.1% | ADD +65.3% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 477,294 | $59.5M | 8.3% | — |
| 4 | STATE STREET CORP | 458,999 | $57.2M | 7.9% | DOUBLED +206.3% |
| 5 | FEDERATED HERMES, INC. | 433,015 | $54.0M | 7.5% | NEW |
| 6 | FRONTIER CAPITAL MANAGEMENT CO LLC | 374,035 | $46.6M | 6.5% | NEW |
| 7 | Woodline Partners LP | 317,517 | $39.6M | 5.5% | — |
| 8 | ALLIANCEBERNSTEIN L.P. | 262,835 | $27.5M | 3.8% | NEW |
| 9 | FMR LLC | 215,808 | $26.9M | 3.7% | DOUBLED +109.8% |
| 10 | GOLDMAN SACHS GROUP INC | 194,179 | $24.2M | 3.4% | — |
| 11 | Artisan Partners Limited Partnership | 193,796 | $24.2M | 3.4% | NEW |
| 12 | Alyeska Investment Group, L.P. | 179,922 | $22.4M | 3.1% | NEW |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 141,600 | $17.7M | 2.5% | — |
| 14 | MORGAN STANLEY | 127,987 | $16.0M | 2.2% | TRIM -42.0% |
| 15 | BALYASNY ASSET MANAGEMENT L.P. | 96,726 | $12.1M | 1.7% | TRIM -34.6% |
| 16 | VANGUARD PORTFOLIO MANAGEMENT LLC | 90,858 | $11.3M | 1.6% | — |
| 17 | Point72 Asset Management, L.P. | 88,160 | $11.0M | 1.5% | NEAR_EXIT -75.6% |
| 18 | VANGUARD FIDUCIARY TRUST CO | 64,783 | $8.1M | 1.1% | — |
| 19 | Clearbridge Investments, LLC | 59,410 | $7.4M | 1.0% | — |
| 20 | Neuberger Berman Group LLC | 49,103 | $6.1M | 0.8% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| JENNISON ASSOCIATES LLC | ADD | 387,483 | 640,611 | +65.3% | $79.9M | 2026-Q1 |
| FRONTIER CAPITAL MANAGEMENT CO LLC | NEW | — | 374,035 | — | $46.6M | 2026-Q1 |
| Alyeska Investment Group, L.P. | NEW | — | 179,922 | — | $22.4M | 2026-Q1 |
| MORGAN STANLEY | TRIM | 220,662 | 127,987 | -42.0% | $16.0M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 30,272 | 37,972 | +25.4% | $4.7M | 2026-Q1 |
| WELLINGTON MANAGEMENT GROUP LLP | ADD | 22,403 | 34,040 | +51.9% | $4.2M | 2026-Q1 |
| FRED ALGER MANAGEMENT, LLC | NEAR_EXIT | 150,026 | 21,236 | -85.8% | $2.6M | 2026-Q1 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | DOUBLED | 2,270 | 17,907 | +688.9% | $2.2M | 2026-Q1 |
| SEI INVESTMENTS CO | ADD | 11,719 | 16,663 | +42.2% | $2.1M | 2026-Q1 |
| Russell Investments Group, Ltd. | DOUBLED | 1,229 | 13,527 | +1000.7% | $1.7M | 2026-Q1 |
| Legal & General Group Plc | ADD | 5,849 | 7,446 | +27.3% | $928.1K | 2026-Q1 |
| STATE OF WISCONSIN INVESTMENT BOARD | ADD | 4,513 | 5,929 | +31.4% | $739.0K | 2026-Q1 |
| Mariner, LLC | TRIM | 11,615 | 4,420 | -61.9% | $551.0K | 2026-Q1 |
| PRICE T ROWE ASSOCIATES INC /MD/ | DOUBLED | 4,090 | 402,564 | +9742.6% | $50.2K | 2026-Q1 |
| CWM, LLC | ADD | 26 | 35 | +34.6% | $4.4K | 2026-Q1 |
| Allworth Financial LP | DOUBLED | 5 | 17 | +240.0% | $2.1K | 2026-Q1 |
| STATE STREET CORP | DOUBLED | 137,251 | 420,462 | +206.3% | $44.0M | 2025-Q4 |
| JENNISON ASSOCIATES LLC | DOUBLED | 106,910 | 387,483 | +262.4% | $40.6M | 2025-Q4 |
| ALLIANCEBERNSTEIN L.P. | NEW | — | 269,027 | — | $28.2M | 2025-Q4 |
| FMR LLC | DOUBLED | 110,446 | 231,760 | +109.8% | $24.3M | 2025-Q4 |
| MORGAN STANLEY | ADD | 138,505 | 220,662 | +59.3% | $23.1M | 2025-Q4 |
| Artisan Partners Limited Partnership | NEW | — | 211,553 | — | $22.1M | 2025-Q4 |
| BALYASNY ASSET MANAGEMENT L.P. | TRIM | 166,535 | 108,880 | -34.6% | $11.4M | 2025-Q4 |
| Point72 Asset Management, L.P. | NEAR_EXIT | 317,309 | 77,297 | -75.6% | $8.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 4,689 | 30,272 | +545.6% | $3.2M | 2025-Q4 |
9 unique insiders with 20 transactions. Net insider value: -$216.5K ($850.0K bought, $1.1M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 10, 2026 | KIRITSY CHRISTOPHER P | Director | AWARD | 3,000 | — | — |
| Jun 10, 2026 | HERON ELAINE J | Director | AWARD | 3,000 | — | — |
| Jun 10, 2026 | JENKINS GEORGE M | Director | AWARD | 3,000 | — | — |
| May 20, 2026 | Goin Kathleen | Chief Operating Officer | EXERCISE | 2,154 | $7.14 | $15.4K |
| May 20, 2026 | Goin Kathleen | Chief Operating Officer | SELL | 3,363 | $110.35 | $371.1K |
| Apr 15, 2026 | Goin Kathleen | Chief Operating Officer | EXERCISE | 2,154 | $7.14 | $15.4K |
| Apr 15, 2026 | Goin Kathleen | Chief Operating Officer | SELL | 1,502 | $125.96 | $189.2K |
| Apr 13, 2026 | Doux John | Director | AWARD | 6,000 | — | — |
| Mar 30, 2026 | JENKINS GEORGE M | Director | BUY | 445 | $112.30 | $50.0K |
| Mar 18, 2026 | Goin Kathleen | Chief Operating Officer | EXERCISE | 2,154 | $7.14 | $15.4K |
| Mar 18, 2026 | Goin Kathleen | Chief Operating Officer | SELL | 2,268 | $117.56 | $266.6K |
| Feb 27, 2026 | HERON ELAINE J | Director | BUY | 2,400 | $125.00 | $300.0K |
| Feb 27, 2026 | JENKINS GEORGE M | Director | BUY | 4,000 | $125.00 | $500.0K |
| Feb 18, 2026 | Goin Kathleen | Chief Operating Officer | EXERCISE | 2,154 | $7.14 | $15.4K |
| Feb 18, 2026 | Goin Kathleen | Chief Operating Officer | SELL | 3,026 | $79.16 | $239.5K |
| Feb 5, 2026 | Kline Ashley Hartmann | Chief Commercial Officer | AWARD | 38,517 | — | — |
| Feb 5, 2026 | Goin Kathleen | Chief Operating Officer | AWARD | 48,956 | — | — |
| Feb 5, 2026 | Korenberg Matthew E | CFO, Treasurer | AWARD | 44,123 | — | — |
| Feb 5, 2026 | Kaupinen Wes | President and CEO | AWARD | 124,603 | — | — |
| Feb 5, 2026 | Martini Jeffrey S | Chief Scientific Officer | AWARD | 64,318 | — | — |
9 SEC filing reports analyzed. Sentiment: 1 bullish, 1 bearish, 1 mixed, 6 neutral. Avg impact: 4.0/10.
NEUTRAL
INST-CLUSTER
3/10
Three mega-passive institutional investors (Vanguard, State Street, Fidelity) significantly increase
Jun 11, 2026
NEUTRAL
8-K
4/10
Palvella Therapeutics announced new Phase 2 TOIVA trial data for QTORIN rapamycin in cutaneous venou
May 15, 2026
NEUTRAL
8-K
2/10
Palvella Therapeutics received approval from Nasdaq to transfer its common stock listing from the Na
May 13, 2026
BEARISH
8-K
6/10
Palvella Therapeutics reported Q1 2026 EPS of -$1.20, missing consensus of -$0.93 by 29%, as R&D and
May 7, 2026
NEUTRAL
PRESS-RELEASE
3/10
Palvella Therapeutics announced it will report Q1 2026 financial results on May 7, 2026, with a conf
Apr 30, 2026
MIXED
8-K
6/10
Palvella Therapeutics reported Q4 2025 financial results with a net loss of $41.7 million ($3.71 per
Apr 21, 2026
NEUTRAL
8-K
3/10
Palvella Therapeutics appointed John Doux, M.D., to its Board of Directors as a Class III member, ef
Apr 13, 2026
BULLISH
CLUSTER
6/10
Two insiders at Palvella Therapeutics, Inc. (PVLA) made open-market purchases totaling $800,000 with
Mar 2, 2026
NEUTRAL
8-K
3/10
Palvella Therapeutics, Inc. announced preliminary cash, cash equivalents, and marketable securities
Feb 24, 2026
BULLISH
7/10
Palvella presented positive Phase 2 TOIVA data at SID showing QTORIN rapamycin statistically signifi
May 15, 2026
BULLISH
8/10
Palvella Therapeutics reported full-year 2025 financial results and provided a significant corporate
Mar 31, 2026
MIXED
6/10
Palvella Therapeutics presented two posters at the 2026 American Academy of Dermatology meeting: one
Mar 27, 2026
NEUTRAL
3/10
Palvella Therapeutics announced it will report its full year 2025 financial results on March 31, 202
Mar 24, 2026
NEUTRAL
4/10
Palvella Therapeutics announced the appointment of Jennifer McDonough as Senior Vice President of Ma
Mar 23, 2026
NEUTRAL
3/10
Palvella Therapeutics launched the 'BEYOND mLM' disease awareness campaign and website (BEYONDmLM.co
Mar 10, 2026
NEUTRAL
5/10
Palvella Therapeutics completed an upsized public offering of 1,840,000 shares at $125.00 per share,
Mar 2, 2026
Current analyst consensus: Strong Buy (96% buy). Based on 23 analysts: 7 strong buy, 15 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$229.60 mean target
+111.0% upside
Strong Buy (1.00)
$205.00 Low
$270.00 High
| Metric | Value |
|---|---|
| Current Price | $108.81 |
| Target Low | $205.00 |
| Target Mean | $229.60 |
| Target Median | $225.00 |
| Target High | $270.00 |
| # Analysts | 15 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-1.16 | $-1.42 | $-0.86 | -34.4% | +0.0% | 2↑ 6↓ | $0.0B | 0.0% | 12 |
| Next Q 2026-09-30 |
$-1.47 | $-1.81 | $-1.05 | -42.2% | +0.0% | 1↑ 1↓ | $0.0B | 0.0% | 12 |
| Current FY 2026-12-31 |
$-5.57 | $-6.91 | $-3.45 | -50.0% | +0.0% | 3↑ 10↓ | $0.0B | 0.0% | 13 |
| Next FY 2027-12-31 |
$-6.82 | $-11.16 | $-1.54 | -22.5% | +0.0% | 1↑ 2↓ | $0.0B | 0.0% | 11 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-1.156 | |
| 7d ago | $-1.170 | +0.014 |
| 30d ago | $-1.156 | |
| 60d ago | $-1.046 | -0.109 |
| 90d ago | $-0.904 | -0.252 |
8 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 21, 2026 | Stephens & Co. | REITERATE | Overweight | Overweight |
| May 21, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| May 12, 2026 | Stephens & Co. | INITIATE | — | Overweight |
| Mar 31, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 16, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Feb 25, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Feb 25, 2026 | BTIG | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | Chardan Capital | MAINTAIN | Buy | Buy |
| Feb 24, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jan 29, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 16, 2026 | BTIG | REITERATE | Buy | Buy |
| Jan 7, 2026 | Mizuho | INITIATE | — | Outperform |
| Dec 16, 2025 | Truist Securities | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | TD Cowen | MAINTAIN | Buy | Buy |
| Dec 16, 2025 | Chardan Capital | MAINTAIN | Buy | Buy |
| Dec 15, 2025 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 7 | 15 | 1 | 0 | 0 | 96% | |
| May 1, 2026 | 6 | 15 | 1 | 0 | 0 | 95% | |
| Apr 1, 2026 | 6 | 15 | 1 | 0 | 0 | 95% | |
| Mar 1, 2026 | 6 | 15 | 1 | 0 | 0 | 95% | |
| Feb 1, 2026 | 6 | 15 | 1 | 0 | 0 | 95% | |
| Jan 1, 2026 | 6 | 14 | 1 | 0 | 0 | 95% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
50°
Neutral
Bearish
Neutral
Bullish
1 mentions
0 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 25, 2026 | 1 | 56° Neutral | 0 | 0 | 1 |
Recent Reddit Threads
Jun 3, 2026
other
Palvella Therapeutics Announces Completion of FDA Pre-NDA Meeting for QTORIN™ Rapamycin in Microcystic Lymphatic Malformations
<p align="center"><em>Palvella remains on track to submit an NDA in the second half of 2026</em></p>
Jun 2, 2026
other
Palvella Therapeutics to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026
<p align="justify">WAYNE, Pa., June 02, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-
May 21, 2026
other
Palvella Therapeutics Named Healthcare & Life Sciences Company of the Year at the Philadelphia Alliance for Capital and Technologies (PACT) Ecosystem Awards
<p align="justify">WAYNE, Pa., May 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=Pw7owL9FxlYDqpwIvwEpfK-avMcqFYh0
May 20, 2026
other
Palvella Therapeutics Presents New SELVA and TOIVA Data at the 2026 International Society for the Study of Vascular Anomalies World Congress Supporting QTORIN™ Rapamycin as a Potential First-in-Disease Therapy for Multiple Serious, Rare Vascular Malformations
<p align="center"><em>In SELVA Phase 3 study, 100% of participants (13/13) aged 6–11 years were rated as “Much Improved” (+2) or “Very Much Improved”
May 15, 2026
fda
Palvella Therapeutics Announces New Data from the Phase 2 TOIVA Trial of QTORIN™ Rapamycin in Cutaneous Venous Malformations Presented at the 83rd Annual Meeting of the Society for Investigative Dermatology
<p align="center"><em>100% of patients with bleeding at baseline demonstrated a statistically significant improvement on the Cutaneous Venous Malforma
May 13, 2026
other
Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market
<p align="center"><em>Uplisting reflects Palvella’s continued progress advancing potential first-in-disease therapies for serious, rare skin diseases
May 7, 2026
earnings
Palvella Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>FDA Pre-New Drug Application (NDA) meeting granted for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformation
May 7, 2026
earnings_calendar
PVLA Q1 2026 Earnings Scheduled — 2026-05-07
May 4, 2026
fda
Palvella Therapeutics Announces First Patients Dosed in Phase 2 LOTU Trial of Fast Track-Designated QTORIN™ Rapamycin for Clinically Significant Angiokeratomas
<p align="center"><em>Clinically significant angiokeratomas represent a rare, chronic and debilitating lymphatic malformation with no FDA-approved the
Apr 30, 2026
earnings
Palvella Therapeutics to Host First Quarter 2026 Financial Results and Corporate Update Conference Call on May 7, 2026
<p align="justify">WAYNE, Pa., April 30, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=-hE0wNT7fYC2hYwjLA2etKvlvxlnDj
Apr 20, 2026
other
Palvella Therapeutics to Present QTORIN™ Rapamycin Results from Phase 3 SELVA and Phase 2 TOIVA Studies at the International Society for the Study of Vascular Anomalies World Congress 2026
<p align="center"><em>James Treat, MD, Professor of Clinical Pediatrics and Dermatology at the Children’s Hospital of Philadelphia to present clinical
Apr 13, 2026
other
Palvella Therapeutics Appoints John D. Doux, M.D., M.B.A., Dermatologist and Recognized Leader in Rare Skin Diseases, to Board of Directors
<p align="center"><em>Physician and seasoned life sciences investor with more than two decades of experience across clinical practice, biotechnology i
Apr 8, 2026
short_interest
FTD: PVLA — 5,810 shares ($0.7M) failed to deliver
Settlement: 20260408, Price: $120.03, FTD Value: $697,374.3, PALVELLA THERAPEUTICS INC NEW
Apr 7, 2026
other
Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
<p align="center"><em>Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice Presiden
Mar 31, 2026
earnings
Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update
<p align="center"><em>New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on t